You are here

Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Long-Acting G-CSF Analog for Treating ARS


    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human Services
  3. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human Services
  4. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human Services
  5. Remote focusing through spatial light modulation for multifocal multiphoton micro


    DESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition schemes to allow imaging of live, moving specimens at high NA. This combination allows for high-resoluti ...

    STTR Phase I 2013 Department of Health and Human Services
  6. Novel Vitamin B6 based prodrugs of gemcitabine

    SBC: MBC Pharma, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): The long-term goal of this proposal is to develop more effective therapies for cancer, specifically pancreatic cancer. The specific focus of this proposal is to improve upon the anti-cancer activity of the drug gemcytabine. This will be accomplished by synthesizing novel conjugates of gemcytabine in a form that enables increased pathways for uptake into cancer ...

    SBIR Phase I 2013 Department of Health and Human Services
  7. Small Molecule Inhibitors of the BCL6 Oncoprotein


    DESCRIPTION (provided by applicant): Chronic pain syndromes affect 25-35% of populations around the world. The presence of chronic pain generates a massive toll on quality of life, workforce productivity and healthcare resource utilization. Although non-opiate medications have been introduced to treat chronic pain syndromes, many types of chronic/neuropathic pain do not respond to such medications ...

    SBIR Phase I 2013 Department of Health and Human Services
  8. Production of human MUC17 (CRD1-L-CRD2) recombinant protein in rice for the treat


    DESCRIPTION (provided by applicant): Recent studies in animal models demonstrate that an endogenous human intestinal mucin fragment, termed MUC17, augments intestinal cell restitution and enhances healing of experimental colitis, potentially opening a newdoor to effective treatment of ulcerative colitis. However, expression of MUC17 in E. coli, yeast, and insect cells has met great challenges due ...

    SBIR Phase I 2013 Department of Health and Human Services
  9. Low-cost proinsulin-transferrin fusion protein in rice for treatment of diabetes


    DESCRIPTION (provided by applicant): Diabetes has become a devastating epidemic worldwide. Insulin is commonly used as a treatment to help manage diabetes because of its ability to control blood glucose levels, and is in high demand worldwide, but it facesmultiple challenges including adverse metabolic side-effects, short in vivo pharmaceutical life, and high cost. Today, millions of people contin ...

    SBIR Phase I 2013 Department of Health and Human Services
  10. Quantum Dot Sensors for Superfund Priority Substances

    SBC: TDA Research, Inc.            Topic: NIEHS

    DESCRIPTION (provided by applicant): The principal aim of this project is to obtain proof-of-concept for a new nanotechnology-based sensor material for rapid and sensitive fluorescence detection of polycyclic aromatic hydrocarbons (PAHs) and polychloro biphenyls (PCBs). Simple, cheap and safe methods to detect and quantify these toxic substances, which rank high in the ATSDR Substance Priority Lis ...

    SBIR Phase I 2013 Department of Health and Human Services
US Flag An Official Website of the United States Government